Research/Development – The News Desk

Startups Are Using AI to Predict Responses to Cancer Drugs

28Dec

By adminNo Comments

World

Startups Are Using AI to Predict Responses to Cancer Drugs

Dec. 28, 2023 12:01 pm ET|WSJ ProBiomedical startups are using artificial intelligence to predict the response patients will have to cancer treatments, aiming to increase the success of drugs in clinical trials and tailor therapies to individuals.As data accumulate from clinical trials and fields such as gene and protein research, AI is helping scientists sift through large volumes of information to uncover signatures that correlate with response—or resistance—to treatment. Startups are using it to predict which drugs are likely to work in clinical studies and create tests to help doctors choose treatments.Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8

Visa Agrees to Acquire Majority Interest in Payments Processor Prosa

16Dec

By adminNo Comments

Money

Visa Agrees to Acquire Majority Interest in Payments Processor Prosa

Visa entered into an agreement to acquire a majority interest in Prosa, a payments processor in Mexico.The payments-networks company said Prosa will operate as an independent company with its own technology infrastructure under the agreement, while Visa looks to expand Prosa’s product offering with new digital solutions, among other efforts.Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8

Championing Diversity From Inside Google

8Dec

By adminNo Comments

World

Championing Diversity From Inside Google

Google has not always been closely associated with words like diversity and inclusion. By its own count, less than 13% of its workforce is Black or Latino, and the company is currently fighting a class-action lawsuit in which plaintiffs allege a “racially biased corporate culture.” Google promised to fix its image-recognition algorithms after a software engineer discovered in 2015 that Google Photos classified him and his Black friends as “gorillas,” but in May the company was forced to acknowledge that it had simply blocked its algorithms from identifying gorillas at all.These are the kinds of issues that Annie Jean-Baptiste must grapple with as the company’s first director of product inclusion and equity. The role is meant to help ensure that people can use what Google offers regardless...

6Dec

By adminNo Comments

World

Health Care Roundup: Market Talk

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET.0902 GMT – Merck’s failure to reach key goals in late-stage clinical trials for its multiple sclerosis drug, evobrutinib, spells an end to its development and shifts the German pharmaceutical company’s focus to cancer drug xevinapant, Citi analysts say in a note. A potential treatment for late-stage head and neck cancer, xevinapant is in phase-3 clinical trials and might be “practice-changing” if it hits the market, say the analysts. They forecast sales of more than EUR1.4 billion, which is 25% ahead of consensus, saying that it is years ahead of competitors. “While evobrutinib’s failure is an obvious setback, we had previously argued the risk-reward was ...

Adobe’s $20B Purchase of Figma Would Harm Innovation, U.K. Regulator Provisionally Finds

28Nov

By adminNo Comments

World

Adobe’s $20B Purchase of Figma Would Harm Innovation, U.K. Regulator Provisionally Finds

The U.K. Competition and Markets Authority said it has provisionally found Adobe’s planned $20 billion acquisition of collaboration-software company Figma would likely harm innovation for software used by the vast majority of U.K. digital designers.The regulator said Tuesday that, following a detailed Phase 2 investigation, it provisionally found the deal would eliminate competition between two main competitors in product-design software, reduce innovation and the development of new competitive products, and remove Figma as a threat to Adobe’s flagship Photoshop and Illustrator products.Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8

OpenAI’s Ineffective Altruists vs. Sam Altman

21Nov

By adminNo Comments

Business

OpenAI’s Ineffective Altruists vs. Sam Altman

Corporate power struggles aren’t rare, and most companies survive them. But the OpenAI board’s sudden ouster of CEO Sam Altman last week looks increasingly like a misguided kamikaze run. It’s hard to see who benefits from the melodrama besides opponents of innovation.News of Mr. Altman’s removal late Friday shocked Silicon Valley. Mr. Altman helped launch OpenAI in 2015 with the mission of responsibly developing artificial intelligence to benefit humanity. He has since become the technology’s public face, with media appearances and testimony to Congress.Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8

Bayer Shares Tumble After Clinical Trial Failure, Loss in Roundup Case

20Nov

By adminNo Comments

World

Bayer Shares Tumble After Clinical Trial Failure, Loss in Roundup Case

Updated Nov. 20, 2023 3:16 pm ETBayer shares fell sharply after the company stopped a late-stage study for a blood-thinning drug early because of lack of efficacy and was told to pay $1.56 billion in a lawsuit relating to its Roundup weedkiller.Bayer said late Sunday that it discontinued a Phase 3 clinical trial to test its experimental drug asundexian for prevention of stroke and systemic embolism for patients with the heart-rhythm disorder atrial fibrillation.Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8

OpenAI Glitch Shows Weaknesses in Microsoft’s AI Armor

20Nov

By adminNo Comments

Money

OpenAI Glitch Shows Weaknesses in Microsoft’s AI Armor

Microsoft may have put out a five-alarm fire around its most important technology move in years. But fires leave scorch marks—and sometimes flare up again. A leadership crisis at Silicon Valley startup OpenAI over the weekend threatened to seriously singe the world’s second-largest company by market value. That is because OpenAI developed the key generative artificial-intelligence technology that has helped power Microsoft’s aggressive move into the field. Microsoft has invested a total of $13 billion into the company and already launched commercial products and services based on its technology, including a chatbot-enabled Bing search engine and a superpowered digital assistant called Copilot that can render emails, spreadsheets and PowerPoint presentations. Copyright ©2023 Dow Jones &...

20Nov

By adminNo Comments

World

OpenAI Glitch Shows Weaknesses in Microsoft’s AI Armor

Microsoft may have put out a five-alarm fire around its most important technology move in years. But fires leave scorch marks—and sometimes flare up again. A leadership crisis at Silicon Valley startup OpenAI over the weekend threatened to seriously singe the world’s second-largest company by market value. That is because OpenAI developed the key generative artificial-intelligence technology that has helped power Microsoft’s aggressive move into the field. Microsoft has invested a total of $13 billion into the company and already launched commercial products and services based on its technology, including a chatbot-enabled Bing search engine and a superpowered digital assistant called Copilot that can render emails, spreadsheets and PowerPoint presentations. Copyright ©2023 Dow Jones &...

17Nov

By adminNo Comments

World

Health Care Roundup: Market Talk

Updated Nov. 17, 2023 12:29 pm ETThe latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET.0846 ET – Twist Bioscience is feeling optimistic about the year ahead after orders picked up and revenue exceeded analyst expectations in its F4Q, which ended Sept. 30. The San Francisco-based biotech company is expecting momentum behind its SynBio product group to be bolstered by Express Genes, its new gene synthesis service, and for its next-generation sequencing business to grow as customers advance their development and commercial plans, CEO Emily Leproust says. Twist is guiding for annual revenue to rise 16% to 18%, with that same growth rate for its SynBio unit. Twist expects 19% to 20% revenue growth for its next-ge...